Neuronetics, Inc. (STIM)
NASDAQ: STIM · Real-Time Price · USD
1.640
-0.050 (-2.96%)
At close: Apr 28, 2026, 4:00 PM EDT
1.680
+0.040 (2.44%)
Pre-market: Apr 29, 2026, 4:01 AM EDT
Company Description
Neuronetics, Inc. engages in providing in office treatments for patients with neurohealth disorders in the United States and internationally.
The company provides NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.
Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood.
The company sells its products through its sales and customer support team to psychiatrists. The company was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.
Neuronetics, Inc.
| Country | United States |
| Founded | 2003 |
| IPO Date | Jun 28, 2018 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 658 |
| CEO | Daniel Reuvers |
Contact Details
Address: 3222 Phoenixville Pike Malvern, Pennsylvania 19355 United States | |
| Phone | 877 600 7555 |
| Website | neurostar.com |
Stock Details
| Ticker Symbol | STIM |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001227636 |
| CUSIP Number | 64131A105 |
| ISIN Number | US64131A1051 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Daniel L. Reuvers | Chief Executive Officer, President and Director |
| Steven E. Pfanstiel C.M.A., M.B.A. | Executive Vice President, Treasurer and Chief Financial Officer |
| W. Andrew Macan J.D. | EVice President, Chief Legal Officer and Corporate Secretary |
| Jeffrey S. Jones | Senior Vice President and Chief of Operations |
| Cory S. Anderson | SVice President and Chief Technology Officer |
| Lisa Metzner-Rosas | Senior Vice President and Chief Marketing Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 10, 2026 | EFFECT | Notice of Effectiveness |
| Apr 9, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 9, 2026 | DEF 14A | Other definitive proxy statements |
| Apr 8, 2026 | SCHEDULE 13D/A | Filing |
| Apr 6, 2026 | 8-K | Current Report |
| Mar 31, 2026 | SCHEDULE 13D | Filing |
| Mar 19, 2026 | 144 | Filing |
| Mar 19, 2026 | 144 | Filing |
| Mar 18, 2026 | SCHEDULE 13G/A | Filing |
| Mar 17, 2026 | S-3 | Registration statement under Securities Act of 1933 |